These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1412 related items for PubMed ID: 26048455

  • 1. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM, Sartor O, Gomella L, Rudo T, Somerville MC, Hereghty B, Manyak MJ.
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [Abstract] [Full Text] [Related]

  • 2. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O, Gomella LG, Gagnier P, Melich K, Dann R.
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 4. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
    Thomsen FB, Brasso K, Christensen IJ, Johansson JE, Angelsen A, Tammela TL, Iversen P, Scandinavian Prostate Cancer Group.
    Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
    Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, van Os S, Hasabou N, Wang F, Bhattacharya S, Heidenreich A.
    Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
    [Abstract] [Full Text] [Related]

  • 6. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
    See WA, Tyrrell CJ, CASODEX Early Prostate Cancer Trialists' Group.
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
    [Abstract] [Full Text] [Related]

  • 7. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
    Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN.
    Urol Int; 2005 Aug; 75(3):217-21. PubMed ID: 16215308
    [Abstract] [Full Text] [Related]

  • 8. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study.
    Klotz L, Drachenberg D, Singal R, Aprikian A, Fradet Y, Kebabdjian M, Zarenda M, Chin J.
    Prostate Cancer Prostatic Dis; 2014 Dec; 17(4):320-4. PubMed ID: 25179591
    [Abstract] [Full Text] [Related]

  • 9. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
    Penson DF, Armstrong AJ, Concepcion R, Agarwal N, Olsson C, Karsh L, Dunshee C, Wang F, Wu K, Krivoshik A, Phung D, Higano CS.
    J Clin Oncol; 2016 Jun 20; 34(18):2098-106. PubMed ID: 26811535
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko B.
    Urology; 2006 Jul 20; 68(1):116-20. PubMed ID: 16844453
    [Abstract] [Full Text] [Related]

  • 11. [Hormonal therapy for prostate cancer: methods and prognosis].
    Huang BX, Su HC, Cao WL, Sun FK.
    Zhonghua Nan Ke Xue; 2013 Sep 20; 19(9):815-9. PubMed ID: 24386861
    [Abstract] [Full Text] [Related]

  • 12. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial.
    Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS.
    Lancet; 2012 Mar 24; 379(9821):1103-11. PubMed ID: 22277570
    [Abstract] [Full Text] [Related]

  • 13. Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial.
    Vaishampayan UN, Heilbrun LK, Monk P, Tejwani S, Sonpavde G, Hwang C, Smith D, Jasti P, Dobson K, Dickow B, Heath EI, Semaan L, Cher ML, Fontana JA, Chinni S.
    JAMA Netw Open; 2021 Jan 04; 4(1):e2034633. PubMed ID: 33496795
    [Abstract] [Full Text] [Related]

  • 14. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
    Axcrona K, Aaltomaa S, da Silva CM, Ozen H, Damber JE, Tankó LB, Colli E, Klarskov P.
    BJU Int; 2012 Dec 04; 110(11):1721-8. PubMed ID: 22500884
    [Abstract] [Full Text] [Related]

  • 15. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 04; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 16. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
    Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, Morganstern DE, Kantoff PW, Taplin ME.
    Urology; 2013 Mar 04; 81(3):611-6. PubMed ID: 23452809
    [Abstract] [Full Text] [Related]

  • 17. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival.
    Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y, Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer.
    Cancer; 2009 Aug 01; 115(15):3437-45. PubMed ID: 19536889
    [Abstract] [Full Text] [Related]

  • 18. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.
    BJU Int; 2006 Jun 01; 97(6):1184-9. PubMed ID: 16686709
    [Abstract] [Full Text] [Related]

  • 19. Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer.
    Gaudet M, Vigneault É, Foster W, Meyer F, Martin AG.
    Radiother Oncol; 2016 Jan 01; 118(1):141-7. PubMed ID: 26702991
    [Abstract] [Full Text] [Related]

  • 20. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG.
    N Engl J Med; 2017 Feb 02; 376(5):417-428. PubMed ID: 28146658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.